Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in Virginia: - Inova Alexandria Hospital — Alexandria, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Inova Loudoun Hospital — Leesburg, Virginia
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Virginia: - Research Site — Blacksburg, Virginia
- Research Site — Fairfax, Virginia
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Virginia: - University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
Phase 2, Phase 3 Recruiting Industry
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT06109272
Sites in Virginia: - Oncology and Hematology Associates of Southwest Virginia /ID# 265834 — Roanoke, Virginia
Phase 2, Phase 3 Recruiting Academic/Other
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition…
Sponsor: Inova Health Care Services
NCT ID: NCT06007846
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Health Care Service — Falls Church, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Virginia: - Inova Schar Cancer Institute — Falls Church, Virginia
- Maryview Hospital, Inc. — Newport News, Virginia
- Bon Secours St. Mary's Hospital — Richmond, Virginia
- VCU Medical Center North Hospital — Richmond, Virginia
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Virginia: - Research Site 102 — Fairfax, Virginia
- Research Site 112 — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Virginia: - USA05-0 — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
Sponsor: RayzeBio, Inc.
NCT ID: NCT06726161
Sites in Virginia: - Research Facility — Charlottesville, Virginia
Phase 2 Recruiting Industry
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Sponsor: AstraZeneca
NCT ID: NCT05775159
Sites in Virginia: - Research Site — Fairfax, Virginia
Phase 2 Recruiting Academic/Other
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Sponsor: Inova Health Care Services
NCT ID: NCT06789757
Sites in Virginia: - Inova Schar Cancer Institute - Fair Oaks — Fairfax, Virginia
- Inova Health Care Service — Falls Church, Virginia
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Virginia: - Exelixis Clinical Site #66 — Charlottesville, Virginia
Phase 1 Recruiting Industry
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT…
Sponsor: Alnylam Pharmaceuticals
NCT ID: NCT06600321
Sites in Virginia: - Clinical Trial Site — Richmond, Virginia
Phase 1 Recruiting Industry
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated incl…
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT06005740
Sites in Virginia: - Virginia Cancer Specialists — Lexington, Virginia
Phase 1 Recruiting Industry
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101wil…
Sponsor: Angiex, Inc.
NCT ID: NCT06440005
Sites in Virginia: - NEXT Oncology — Fairfax, Virginia
Phase 1 Recruiting Industry
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerab…
Sponsor: Conjupro Biotherapeutics, Inc.
NCT ID: NCT07317505
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Virginia: - Massive Bio SYNERGY-AI site — Charlottesville, Virginia
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Virginia: - Sentara Martha Jefferson Hospital — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Sentara Norfolk General Hospital — Norfolk, Virginia
- VCU Massey Cancer Center at Stony Point — Richmond, Virginia
Recruiting Industry
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristic…
Sponsor: HistoSonics, Inc.
NCT ID: NCT06486454
Sites in Virginia: - Henrico Doctors' Hospital — Richmond, Virginia
Phase 4 Recruiting Academic/Other
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection…
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT06084234
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia